Kobayashi Pharmaceutical Co., Ltd.
2026 Consolidated Interim Financial Results for the 2nd Quarter (Mid-Term) under Japanese GAAP
Net sales for the interim period were ¥70,749 million, up 2.5% year over year. Operating income was ¥2,162 million, down 67.5% YoY. Ordinary income was ¥3,006 million, down 58.5% YoY. Net income attributable to owners of the parent was ¥1,136 million, down 64.1% YoY. Full-year guidance unchanged. Proposed dividends: an interim dividend of ¥45 per share at the end of the second quarter and a ¥61 per share forecast at the end of the third quarter, for a total of ¥106 per share for the year. Segments remain robust domestically, but profits were eroded by international and Cairo-related pressures. Notable items include product recall-related losses and costs related to plant consolidation.
Key Figures
- Sales: ¥70,749 million (YoY +2.5%)
- Operating income: ¥2,162 million (YoY △67.5%)
- Net income attributable to owners of the parent: ¥1,136 million (YoY △64.1%)
AI要約
Overview of Results
Net sales for the interim period reached ¥70,749 million, marking a 2.5% year-over-year increase, while operating income declined sharply to ¥2,162 million. Domestic segments remained solid due to new product effects, but international operations saw declines in revenue and profit due to factors such as U.S. supply issues, pressuring overall profitability. Interim net income also fell to ¥1,136 million. Full-year guidance remains unchanged.
Outlook and Key Items
Key factors behind the substantial YoY decline include the occurrence of extraordinary gains and losses, foreign exchange impacts, and higher energy costs. Notable items include compensation and recall costs related to products containing red yeast rice, plant consolidation costs, and losses from asset disposals by subsidiaries. The full-year earnings forecast for 2026 remains as stated in the financial summary. Going forward, overseas market trends and risk management of raw materials and logistics are expected to be key to the earnings recovery.
Kobayashi Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
